Multimodal treatment, long-term outcome, and experience of intracranial meningeal hemangiopericytomas

Abstract

Intracranial meningeal hemangiopericytoma (M-HPC) is a rare, highly cellular and vascularized mesenchymal tumor that is characterized by high tendency for recurrence and extraneural metastasis.Preoperative images such as CT, MRI, and angiography are necessary for the useful information of M-HPC, although M-HPC shares similar clinical manifestations with meningioma. In distinction from others, radical resection including the attaching dura or dural sinus following adjuvant postoperative radiotherapy remains the cornerstone of therapy in M-HPC. Recently, positive STAT6 immunostaining of the tumor showed that the tumor is different from meningioma, and is the same with the entity of solitary fibrous tumor (SFT). But, advanced molecular study about NAB2-STAT6 fusion gene support the concept that classic SFT and M-HPC are separate groups that share common features but correlate to different clinical outcome.